We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

82 hedge funds and large institutions have $476M invested in Adaptimmune Therapeutics in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 22 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 22

0% more call options, than puts

Call options by funds: $692K | Put options by funds: $691K

0.65% less ownership

Funds ownership: 12.62% → 11.97% (-0.65%)

2% less funds holding

Funds holding: 84 → 82 (-2)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

24% less capital invested

Capital invested by funds: $624M → $476M (-$148M)

Holders
82
Holders Change
-2
Holders Change %
-2.38%
% of All Funds
1.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
27
Reduced
22
Closed
12
Calls
$692K
Puts
$691K
Net Calls
+$1K
Net Calls Change
+$127K

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$5.47M
2
ECM
Endurant Capital Management
California
+$3.03M
3
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
+$2.76M
4
GCP
GSA Capital Partners
United Kingdom
+$2.04M
5
Goldman Sachs
Goldman Sachs
New York
+$1.62M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$11.8M
2
Citadel Advisors
Citadel Advisors
Florida
-$11.3M
3
ACA
Avoro Capital Advisors
New York
-$7.4M
4
Millennium Management
Millennium Management
New York
-$3.33M
5
OAMG
Odey Asset Management Group
United Kingdom
-$2.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
26
ALPS Advisors
Colorado
$872K -$364K -75,040 -27%
Citadel Advisors
27
Citadel Advisors
Florida
$642K -$11.3M -2,324,950 -94%
JF
28
Jump Financial
Illinois
$546K +$622K +128,200 New
AA
29
AlphaCentric Advisors
Puerto Rico
$511K +$335K +69,000 +135%
SFI
30
Susquehanna Fundamental Investments
Pennsylvania
$510K -$194K -39,940 -25%
WM
31
WS Management
Florida
$492K – – –
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$469K +$287K +59,166 +116%
Man Group
33
Man Group
United Kingdom
$438K -$157K -32,344 -24%
Vontobel Holding
34
Vontobel Holding
Switzerland
$426K – – –
Geode Capital Management
35
Geode Capital Management
Massachusetts
$309K – – –
Mitsubishi UFJ Asset Management
36
Mitsubishi UFJ Asset Management
Japan
$259K -$78K -16,072 -21%
VWM
37
Vigilare Wealth Management
Arizona
$231K +$81.8K +16,850 +45%
Group One Trading
38
Group One Trading
Illinois
$220K +$173K +35,672 +222%
KBC Group
39
KBC Group
Belgium
$220K +$184K +38,000 +275%
Citigroup
40
Citigroup
New York
$213K -$175K -36,078 -42%
VEA
41
Virtus ETF Advisers
New York
$212K -$114K -23,418 -32%
Stifel Financial
42
Stifel Financial
Missouri
$185K +$47.3K +9,736 +29%
HJIM
43
Henry James International Management
New York
$183K -$209K -43,000 -50%
DekaBank Deutsche Girozentrale
44
DekaBank Deutsche Girozentrale
Germany
$181K – – –
HF
45
HRT Financial
New York
$181K +$207K +42,621 New
Jane Street
46
Jane Street
New York
$130K +$60.1K +12,381 +68%
PCS
47
Personal CFO Solutions
New Jersey
$129K +$80.1K +16,500 +119%
Janney Montgomery Scott
48
Janney Montgomery Scott
Pennsylvania
$128K – – –
Credit Agricole
49
Credit Agricole
France
$128K +$146K +30,000 New
ProShare Advisors
50
ProShare Advisors
Maryland
$104K +$27.6K +5,680 +30%
1
2
3 4

ADAP Hedge Fund Activity: Q2 2021 in Review

82 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2021, worth a combined $476M — down 24% from $624M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ADAP and 10 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 27 added.

The largest buyer was PFM Health Sciences, adding an estimated $5.47M. The largest seller was Morgan Stanley, cutting an estimated $11.8M.

  • 82 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2021, down from 84 in Q1 2021.
  • Funds reported $476M of Adaptimmune Therapeutics stock for Q2 2021, down 24% quarter-over-quarter.
  • 10 funds opened new Adaptimmune Therapeutics positions in Q2 2021 and 12 closed out, a net change of -2 holders.
  • The largest Adaptimmune Therapeutics buyer in Q2 2021 was PFM Health Sciences, an estimated $5.47M added.
  • The largest Adaptimmune Therapeutics seller in Q2 2021 was Morgan Stanley, an estimated $11.8M sold.

Based on aggregated 13F filings for Q2 2021.